Bristol-Myers Squibb's Baraclude has $314 million in US annual sales.
On Thursday, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) announced that the Appeals for the Federal Circuit today upheld a ruling by the US District Court for the District of Delaware finding Bristol-Myers Squibb Inc.'s (NYSE: BMY) entecavir compound patent claim invalid. The US Food and Drug Administration (FDA) has granted tentative approval for Teva's generic entecavir, marketed as Baraclude, for the treatment of breast cancer. Teva will finalize the launch plans for this product when it receives final approval from the FDA.
Brand Baraclude had $314 million in US sales in the 12 months through March 2014, according to IMS.
Published by Globes [online], Israel business news - www.globes-online.com - on June 15, 2014
© Copyright of Globes Publisher Itonut (1983) Ltd. 2014